REDWOOD CITY, Calif.--(BUSINESS WIRE)--Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of ...

Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--#COVID19--Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--#COVID19--Meissa Vaccines (“Meissa”), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced interim ...

Meissa Vaccines is putting its portfolio on hold and laying off staff due to the current fundraising environment, the company told Fierce Biotech. While Meissa touts a phase 2/3-ready RSV ...

Meissa Vaccines has raised $30 million to advance a pipeline of vaccines to prevent viral respiratory infections. The series A equips Meissa to run phase 1 and 2 trials of a respiratory syncytial ...

Meissa Vaccines has presented early clinical data on its nasal COVID-19 vaccine, revealing the highest dose of the recombinant live attenuated candidate triggered similar nasal antibody levels to ...

2021 Status: Meissa said March 16 that it received clearance from the FDA for a Phase 1 clinical study of MV-014-212. The Phase 1, open-label, dose-escalation study (NCT04798001) is designed to ...

Meissa Vaccines has appointed Frank Glavin as chief executive officer. Co-founder Dr. Martin Moore will serve as chief scientific officer of the company, which develops vaccines for respiratory ...